Filed Under (Cancer) by David on 01-04-2010
0
Bayer HealthCare and Onyx have announced that the supplemental New Drug Application (sNDA) for sorafenib tablets (Nexavar), indicated for patients with hepatocellular carcinoma (HCC), has been accepted for review and has been granted priority review status by the FDA. HCC is the most common form of liver cancer.
Read the rest of this entry »
Filed Under (Anti Viral, Cancer) by David on 29-01-2010
0
A supplemental New Drug Application (sNDA) has been approved for sorafenib tablets (Nexavar, Bayer/Onyx) to treat unresectable hepatocellular carcinoma. This form of liver cancer is responsible for almost 90% of primary malignant liver tumors in adults.
Hepatocellular carcinoma is extremely aggressive. If the cancer isn’t removed completely through surgery, patients usually die within six months.
Read the rest of this entry »
